URGENT UPDATE: Nearly 581,000 bottles of high blood pressure medication have been recalled due to the presence of potentially cancer-causing chemicals. Teva Pharmaceuticals announced the voluntary recall of prazosin hydrochloride capsules on October 7, 2023, after testing revealed elevated levels of a carcinogen.
The FDA classified the recall as Class II risk on October 24, indicating that exposure to the medication “may cause temporary or medically reversible adverse health consequences.” This recall encompasses three dosage strengths of the drug distributed nationwide, impacting patients who use it for various conditions, including high blood pressure and prostate issues. Notably, it is also prescribed off-label for symptoms of post-traumatic stress disorder (PTSD).
The recalled medications include:
– **1 mg capsules:** 181,659 bottles (NDC 0093-4067-01 and 0093-4067-10) with lot numbers 3010544A and 3010545A, expiring in October 2025.
– **2 mg capsules:** 291,512 bottles (NDC 0093-4068-01 and 0093-4068-10) across multiple lot numbers, expiring between October 2025 and July 2026.
– **5 mg capsules:** 107,673 bottles (NDC 0093-4069-01, 0093-4069-52, and 0093-4069-05) across various lot numbers, with expiration dates extending into 2026.
Patients currently taking the recalled medication are urged to consult with their healthcare provider immediately, as abruptly stopping blood pressure medication can lead to serious health risks. Teva Pharmaceuticals has begun notifying affected customers via letter, and the recall process is ongoing.
For those concerned about their medication, it is crucial to contact a healthcare provider or pharmacist to determine if their specific bottles are included in the recall and discuss alternative treatment options.
As this situation develops, more information will be available from official sources like the FDA and Teva Pharmaceuticals. Stay informed and prioritize your health by ensuring the safety of your medications.
